As described in my first article, the noninvasive prenatal testing ("NIPT") market is evolving at a pace that has rarely been seen in healthcare. This nascent market provides a compelling opportunity for investors able to see it through a fog of uncertainty. Sequenom (SQNM) has maintained market leadership, since their launch of MaterniT21 in October 2011. The investment challenge: decipher the financial reporting in order to recognize the value proposition.
Supplement the financials with performance metrics. The objectives of financial reporting include providing:
· Valuable information to existing and prospective investors, employees, and creditors.
· Content to determine the economic resources and obligations of an enterprise.
· Reports to assess the amounts, timing and uncertainties of prospective...